Detalles de la búsqueda
1.
Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort study.
Hepatology
; 78(6): 1858-1866, 2023 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37203233
2.
Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis.
Hepatology
; 77(5): 1746-1756, 2023 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36633913
3.
Glycemic control target for liver and cardiovascular events risk in metabolic dysfunction-associated steatotic liver disease.
Hepatol Res
; 2024 Feb 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-38400797
4.
Concordance between metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease.
Hepatol Res
; 2024 Jan 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38234088
5.
Impact of immune-related adverse events in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
J Gastroenterol Hepatol
; 2024 Mar 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38494668
6.
Two-Step Strategy, FIB-4 Followed by Magnetic Resonance Elastography, for Detecting Advanced Fibrosis in NAFLD.
Clin Gastroenterol Hepatol
; 21(2): 380-387.e3, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35123096
7.
Liver Stiffness on Magnetic Resonance Elastography and the MEFIB Index and Liver-Related Outcomes in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Individual Participants.
Gastroenterology
; 163(4): 1079-1089.e5, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35788349
8.
Long-term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety.
Am J Gastroenterol
; 2023 Aug 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37561058
9.
Multivariable Quantitative US Parameters for Assessing Hepatic Steatosis.
Radiology
; 309(1): e230341, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37787670
10.
Effect of fatty liver and fibrosis on hepatocellular carcinoma development in patients with chronic hepatitis B who received nucleic acid analog therapy.
J Viral Hepat
; 30(4): 297-302, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36648382
11.
Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B.
J Med Virol
; 95(1): e28210, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36222204
12.
Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group.
Invest New Drugs
; 41(2): 340-349, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36995548
13.
Pseudomonas paralcaligenes sp. nov., isolated from a hospitalized patient.
Int J Syst Evol Microbiol
; 73(1)2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36748583
14.
Risk of cardiovascular disease in lean patients with nonalcoholic fatty liver disease.
BMC Gastroenterol
; 23(1): 211, 2023 Jun 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-37330485
15.
Alanine aminotransferase levels as therapeutic targets after nucleotide/nucleoside analog therapy in patient with chronic hepatitis B.
Hepatol Res
; 53(1): 35-42, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36117296
16.
Usefulness of neutrophil-to-lymphocyte ratio in predicting progression and survival outcomes after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
Hepatol Res
; 53(1): 61-71, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36070216
17.
Prediction Model with HLA-A*33:03 Reveals Number of Days to Develop Liver Cancer from Blood Test.
Int J Mol Sci
; 24(5)2023 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36902191
18.
Risk Difference of Liver-Related and Cardiovascular Events by Liver Fibrosis Status in Nonalcoholic Fatty Liver Disease.
Clin Gastroenterol Hepatol
; 20(5): 1171-1173.e2, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34280550
19.
Utility of Ultrasound-Guided Attenuation Parameter for Grading Steatosis With Reference to MRI-PDFF in a Large Cohort.
Clin Gastroenterol Hepatol
; 20(11): 2533-2541.e7, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34768008
20.
Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicentre study by the Japanese Red Cross Liver Study Group.
J Viral Hepat
; 29(7): 551-558, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35548866